Cardiome -- CRME Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME

CRME 2.330

-2.1%

May 16 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (8)	7/12/2006 5:49:02 AM
From: zeta1961	Read Replies (1) of 285

,Great discussion and here's the opinion of a long-time long..Garren and I realize that he doesn't have the vaunted reputation in '05...I also read Ian's response to the latest PR..had I not known of NBIX, I'd take the cardiome exec's at their word..there's nothing in there to make me think that the clinical data is a problem.. Cardiome (CRME) reported that they met with the FDA and are discussing an update for investors—I would expect a conference call soon to give feedback to investors. For the moment I am standing by my earlier thesis that management is being transparent in that most of the filing problems were clerical in nature (the company got a RTF—refusal to file letter --on the NDA that Astellas filed for the IV formulation of RSD1235). I now expect data on the 300mg oral bid dose of RSD1235 in early August—the results will still be blinded but again we may see the two groups (placebo and drug) separate in terms of how many patients remain in sinus rhythm at day 28 post cardioversion. I remain long CRME (search alert archives for more information). The stock recently moved up some—I would be a buyer under $8.50.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next